Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | IKBKB | O14920 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 2/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960184 | 0.81 | DAO (0.48) | S1PR1S1PR3S1PR2S1PR4HDAC8 | |
| SCHEMBL352339 | 0.79 | L3MBTL1 (0.56) | S1PR1S1PR3S1PR2S1PR4HDAC8 | |
| SCHEMBL10638684 | 0.79 | S1PR1 (0.41) | F2S1PR1S1PR3S1PR2S1PR4 | |
| SCHEMBL6181512 | 0.77 | F2 (0.71) | F2IKBKBALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL28933254 | 0.75 | HDAC8 (0.37) | S1PR1S1PR3S1PR2S1PR4HDAC8 | |
| SCHEMBL20786824 | 0.75 | KDM4E (0.49) | S1PR1S1PR3S1PR2S1PR4HDAC8 | |
| SCHEMBL2226439 | 0.75 | NPSR1 (0.51) | S1PR1S1PR3S1PR2S1PR4HDAC8 | |
| SCHEMBL6284311 | 0.75 | GSK3B (0.56) | S1PR1S1PR3S1PR2S1PR4HDAC8 | |
| SCHEMBL15113608 | 0.75 | S1PR1 (0.39) | S1PR1S1PR3S1PR2S1PR4HDAC8 | |
| SCHEMBL12670964 | 0.74 | S1PR1 (0.50) | S1PR1S1PR3S1PR2S1PR4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2016053855-A1 | SPHINGOSINE-1-PHOSPATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-04-07 | — | — | WO | disclosed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-6613930-B2 | Contacting 2-amino-4-nitrotoluene with HR/NaNO3 followed by heating; hydrogenation to reduce nitro group to amino group; reacting with NaNO2/HCl; adding cyanate source; oxidation to obtain 4-cyanobenzoic acid derivative | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-1244613-A2 | METHODS FOR PRODUCING CYANOBENZOIC ACID DERIVATIVES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020072626-A1 | Methods for producing 3-cyano- and 4-cyano-benzoic acid derivative compounds | COR THERAPEUTICS, INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2001042198-A2 | METHODS FOR PRODUCING CYANOBENZOIC ACID DERIVATIVES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998042347-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072626-A1 | Methods for producing 3-cyano- and 4-cyano-benzoic acid derivative compounds | PFKP, PCCA, TBXAS1 | F2 11/4885IKBKB 1155/4885S1PR1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.